[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 546,415
  • Shares Outstanding, K 69,874
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,000 K
  • EBIT $ -143 M
  • EBITDA $ -142 M
  • 60-Month Beta 0.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.80

Options Overview Details

View History
  • Implied Volatility 112.36% (+14.79%)
  • Historical Volatility 80.20%
  • IV Percentile 47%
  • IV Rank 12.54%
  • IV High 387.48% on 06/04/26
  • IV Low 72.91% on 01/22/26
  • Expected Move (DTE 29) 1.32 (17.04%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,324
  • Volume Avg (30-Day) 2,024
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 33,041
  • Open Int (30-Day) 28,901
  • Expected Range 6.41 to 9.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 1
  • High Estimate $-0.80
  • Low Estimate $-0.80
  • Prior Year $-1.10
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.96 +55.85%
on 06/24/26
8.45 -8.52%
on 07/21/26
+2.88 (+59.38%)
since 06/23/26
3-Month
3.76 +105.59%
on 06/09/26
8.45 -8.52%
on 07/21/26
+1.98 (+34.43%)
since 04/23/26
52-Week
3.76 +105.59%
on 06/09/26
9.12 -15.24%
on 12/30/25
-0.03 (-0.39%)
since 07/23/25

Most Recent Stories

More News
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program

HELP : 7.73 (-1.15%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 7.73 (-1.15%)
CMPS : 11.71 (-1.84%)
ATAI : 7.17 (-0.14%)
JNJ : 259.27 (+1.42%)
LLY : 1,185.87 (+1.97%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program  Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data...

HELP : 7.73 (-1.15%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability...

HELP : 7.73 (-1.15%)
HELP.NE : 10.9200 (-1.09%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 7.73 (-1.15%)
CMPS : 11.71 (-1.84%)
GHRS : 27.63 (-3.32%)
JNJ : 259.27 (+1.42%)
DFTX : 42.93 (-1.69%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 7.73 (-1.15%)
CMPS : 11.71 (-1.84%)
GHRS : 27.63 (-3.32%)
JNJ : 259.27 (+1.42%)
DFTX : 42.93 (-1.69%)
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE,...

HELP : 7.73 (-1.15%)
HELP.NE : 10.9200 (-1.09%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.73 (-1.15%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.73 (-1.15%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.73 (-1.15%)

Business Summary

Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 8.53
2nd Resistance Point 8.34
1st Resistance Point 8.04
Last Price 7.73
1st Support Level 7.55
2nd Support Level 7.36
3rd Support Level 7.06

See More

52-Week High 9.12
Last Price 7.73
Fibonacci 61.8% 7.07
Fibonacci 50% 6.44
Fibonacci 38.2% 5.81
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.